Skip header and navigation

Narrow By

35 records – page 1 of 2.

Biotargets of Cancer in Current Clinical Practice

https://libcat.nshealth.ca/en/permalink/provcat31016
Mauro Bologna, editor. --New York, NY: Humana Press , c2012.
Available Online
View e-Book
Location
Online
Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (in…
Available Online
View e-Book
Other Authors
Bologna, Mauro
Responsibility
Mauro Bologna, editor
Place of Publication
New York, NY
Publisher
Humana Press
Date of Publication
c2012
Physical Description
1 online resource (xvi, 563 p. : 100 ill., 57 ill. in color)
Series Title
Current clinical pathology
ISBN
9781617796159
Subjects (MeSH)
Biological Markers
Molecular Targeted Therapy
Neoplasms - therapy
Subjects (LCSH)
Medical laboratories
Oncology
Pathology
Abstract
Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (individualized) therapy through biotarget-specific new molecular treatments, with the latest information on the validation status of each novel biomarker. Individual chapters are dedicated to the major cancer types, plus a special chapter on metastasis. The present debate on patentability of genetic information applied to diagnostics and therapeutics of cancer is also discussed.
Contents
Central Nervous System Tumors -- Head and Neck Tumors -- Thyroid Cancer -- Targeted Therapies for Non-Small Cell Lung Cancer -- Non-Hodgkin Lymphomas -- Leukemias -- Breast Cancer -- Esophago-Gastric Cancer -- Colorectal Cancer -- Hepatocellular Carcinoma -- Biomarkers for Prognosis and Molecularly Targeted Therapy in Renal Cell Carcinoma -- Bladder Cancer -- Biomarkers in Prostate cancer -- Ovarian Cancer -- Uterine Cancer: The Influence of Genetics and Environment on Cell Cycling Pathways in Cancer -- Biotargets in Sarcomas: The Past, Present and a Look into the Future -- Melanoma and other skin cancers -- Molecular pathology of cancer metastasis: suggestions for future therapy -- Current and future developments in cancer therapy research: miRNAs as new promising targets or tools.
Format
e-Book
Location
Online
Less detail

BRAF Targets in Melanoma : Biological Mechanisms, Resistance, and Drug Discovery

https://libcat.nshealth.ca/en/permalink/provcat39005
Ryan J. Sullivan, editor. --New York, NY: Springer , c2015.
Available Online
View e-Book
Location
Online
This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researcher…
Available Online
View e-Book
Other Authors
Sullivan, Ryan J
Responsibility
Ryan J. Sullivan, editor
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2015
Physical Description
1 online resource (viii, 204 p. : 26 illus., 21 illus. in color)
Series Vol.
82
Series Title
Cancer drug discovery and development
ISBN
9781493921430
9781493921423 (print ed.)
ISSN
2196-9906
Subjects (MeSH)
Melanoma - drug therapy
Melanoma - genetics
Molecular Targeted Therapy - methods
Protein Kinase Inhibitors - therapeutic use
Proto-Oncogene Proteins B-raf - antagonists & inhibitors
Abstract
This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.
Contents
1. Melanoma: Historical Context -- 2. Melanoma Pathogenesis -- 3. Molecular Diagnostics and Tumor Mutational Analysis -- 4. Clinical Utility of BRAF-Targeted Therapy in Melanoma -- 5. The Ethics of Randomized Trials in Oncology -- 6. Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- 7. Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy -- 8. Combination BRAF-Directed Therapy and Immunotherapy -- 9. Moving Forward: Making BRAF-Targeted Therapy Better.
Format
e-Book
Location
Online
Less detail

Chemotherapy for Leukemia : Novel Drugs and Treatment

https://libcat.nshealth.ca/en/permalink/provcat41976
Takanori Ueda, editor. --Singapore: Springer , 2017.
Available Online
View e-Book
Location
Online
This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor …
Available Online
View e-Book
Other Authors
Ueda, Takanori
Responsibility
Takanori Ueda, editor
Place of Publication
Singapore
Publisher
Springer
Date of Publication
2017
Physical Description
1 online resource (viii, 361 pages) : 82 illus., 51 illus. in color
ISBN
9789811033322
9789811033308 (print ed.)
Subjects (MeSH)
Antimetabolites, Antineoplastic
Leukemia - drug therapy
Molecular Targeted Therapy
Abstract
This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells. This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also oncologists, all physicians who specialize in blood cancer, and pharmacologists who are involved in the development of therapeutic agents for leukemia.
Contents
1. An Overview -- Part I: Bcr-Abl Tyrosine Kinase Inhibitors (TKIs) -- 2. Imatinib: Basic Results -- 3. Imatinib: Clinical Pharmacology and Therapeutic Results -- 4. Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIs -- Part II: New Antibodies for Leukemia -- 5. Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results -- 6. Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results -- 7. Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results -- 8. Blinatumomab for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results -- 9. Mogamulizumab in Adult T-cell Leukemia/Lymphoma -- Part III: Signaling inhibitors -- 10. FLT3 inhibitors -- Part IV: Differentiating Agents -- 11. Retinoic Acid, All-Trans Retinoic Acid (ATRA) and Tamibarotene -- 12. The Molecular Basis of Arsenic Trioxide Treatment for Acute Promyelocytic Leukemia (APL) -- 13. Arsenic Trioxide: Clinical Pharmacology and Therapeutic Results -- Part V: New Chemotherapeutic Agents Including Antimetabolite -- 14. Nelarabine -- 15. Forodesine -- 16. Clofarabine: Structure, Mechanism of Action, and Clinical Pharmacology -- 17. Clinical Use of Clofarabine for Adults and Children with Leukemia -- 18. Re-Emerging Antimetabolites with Novel Mechanism of Action with Respect to Epigenetic Regulation: Basic Aspects -- 19. Epigenetic Regulator, Re-Emerging Antimetabolites with Novel Mechanism of Action (Azacitidine and Decitabine): Clinical Pharmacology and Therapeutic Results -- Part VI: Therapy Targeting Leukemic Stem Cells -- 20. Therapies Targeting Leukemic Stem Cells.
Format
e-Book
Location
Online
Less detail

Childhood Acute Lymphoblastic Leukemia

https://libcat.nshealth.ca/en/permalink/provcat41348
Ajay Vora, editor. --Cham: Springer , 2017.
Available Online
View e-Book
Location
Online
This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive c…
Available Online
View e-Book
Other Authors
Vora, Ajay
Responsibility
Ajay Vora, editor
Place of Publication
Cham
Publisher
Springer
Date of Publication
2017
Physical Description
1 online resource (ix, 342 pages) : 38 illus., 30 illus. in color
ISBN
9783319397085
9783319397078 (print ed.)
Subjects (MeSH)
Immunotherapy
Molecular Targeted Therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Abstract
This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.
Contents
1. Epidemiology and Etiology of Childhood ALL -- 2. Clinical Presentation and Prognostic Factors -- 3. Diagnostic Flow Cytometry and Immunophenotypic Classification -- 4. Cytogenetics and Molecular Genetics -- 5. Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Antileukemic Drugs -- 6. Minimal Residual Disease (MRD) Diagnostics: Methodology and Prognostic Significance -- 7. First Line Treatment: Current Approach -- 8. Targeted Therapy and Precision Medicine -- 9. Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia -- 10. Cellular Therapy -- 11. Relapsed Acute Lymphoblastic Leukemia of Childhood -- 12. Medical Supportive Care for Treatment-Related Toxicity in Childhood ALL -- 13. Developing World Perspective.
Format
e-Book
Location
Online
Less detail

DNA and Histone Methylation as Cancer Targets

https://libcat.nshealth.ca/en/permalink/provcat41841
Atsushi Kaneda, Yu-ichi Tsukada, editors. --Cham: Humana Press , 2017.
Available Online
View e-Book
Location
Online
This book will focus on DNA and histone methylation in epigenetics and describe how it is involved in the molecular mechanisms responsible for the development of cancer. Chapters will summarize the current knowledge of the molecular basis of DNA and histone methylation and explain how it is involved in cancer, describe the features of DNA and histone methylation associated with particular types of cancer, diagnostic/therapeutic applications, and future directions of DNA and histone methylation …
Available Online
View e-Book
Other Authors
Kaneda, Atsushi
Tsukada, Yu-ichi
Responsibility
Atsushi Kaneda, Yu-ichi Tsukada, editors
Place of Publication
Cham
Publisher
Humana Press
Date of Publication
2017
Physical Description
1 online resource (viii, 624 pages) : 91 illus., 81 illus. in color
Series Title
Cancer drug discovery and development
ISBN
9783319597867
9783319597843 (print ed.)
ISSN
2196-9906
Subjects (MeSH)
DNA Methylation
Epigenesis, Genetic
Histones
Molecular Targeted Therapy
Neoplasms - genetics
Abstract
This book will focus on DNA and histone methylation in epigenetics and describe how it is involved in the molecular mechanisms responsible for the development of cancer. Chapters will summarize the current knowledge of the molecular basis of DNA and histone methylation and explain how it is involved in cancer, describe the features of DNA and histone methylation associated with particular types of cancer, diagnostic/therapeutic applications, and future directions of DNA and histone methylation as cancer targets.
Contents
DNA and histone methylation in epigenetics -- The molecular basis of DNA methylation -- The molecular basis of DNA demethylation -- DNA methylation changes in cancer -- Misregulation of DNA methylation regulators in cancer -- The molecular basis of histone methylation -- The molecular basis of histone demethylation -- Misregulation of histone methylation regulators in cancer -- Other histone modifications -- DNA methylation and dysregulation of miRNA in cancer -- Genomic imprinting syndromes and cancer -- DNA and histone methylation in brain cancer -- DNA and histone methylation in gastric cancer -- DNA and histone methylation in hematopoietic malignancy -- DNA and histone methylation in lung cancer -- DNA and histone methylation in liver cancer -- DNA and histone methylation in colon cancer -- DNA and histone methylation in prostate cancer -- DNA and histone modifications in cancer diagnosis -- DNA and histone modifications in cancer therapy -- Future perspective of DNA and histone methylation as cancer targets.
Format
e-Book
Location
Online
Less detail

Innovations for Next-Generation Antibody-Drug Conjugates

https://libcat.nshealth.ca/en/permalink/provcat43016
Marc Damelin, editor. --Cham: Humana Press , c2018.
Available Online
View e-Book
Location
Online
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field's history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for soli…
Available Online
View e-Book
Other Authors
Damelin, Marc
Responsibility
Marc Damelin, editor
Place of Publication
Cham
Publisher
Humana Press
Date of Publication
c2018
Physical Description
1 online resource (viii, 357 p.) : 70 illus., 52 illus. in color
Series Title
Cancer drug discovery and development
ISBN
9783319781549
9783319781532 (print ed.)
9783319781556 (print ed.)
ISSN
2196-9906
Subjects (MeSH)
Antineoplastic Agents - pharmacology
Drug Design
Immunoconjugates
Molecular Targeted Therapy
Neoplasms - drug therapy
Specialty
Medical Oncology
Pharmacology
Abstract
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field's history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Contents
1. Introduction: Motivations for Next-Generation ADCs -- 2. Combining ADCs with Immuno-oncology Agents -- 3. Improving the Safety Profile of ADCs -- 4. Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development -- 5. Regulatory Considerations and Companion Diagnostics -- 6. ADC Process Development and Manufacturing -- 7. HER2-Targeted ADCs: At the Forefront of ADC Technology Development -- 8. Next Generation Payloads for ADCs -- 9. Delivering More Payload: High DAR ADCs -- 10. Site-Specific Antibody Drug Conjugates -- 11. Bispecific and Biparatopic Antibody-Drug Conjugates -- 12. Drug Conjugates to the Tumor Microenvironment: Probody Drug Conjugates -- 13. Antibody-Drug Conjugates: Targeting the Tumor Microenvironment -- 14. Next Horizons: ADCs Beyond Oncology.
Format
e-Book
Location
Online
Less detail

Management of castration resistant prostate cancer

https://libcat.nshealth.ca/en/permalink/provcat34052
Fred Saad, Mario A. Eisenberger, editors. --New York: Humana Press , c2014.
Available Online
View e-Book
Location
Online
This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in-depth review of proven therapeutic options, including bone-targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigation are also reviewed. The text provides up-to-date guidelines and algorithms for the management of CRPC bas…
Available Online
View e-Book
Other Authors
Saad, Fred
Eisenberger, Mario A.
Responsibility
Fred Saad, Mario A. Eisenberger, editors
Place of Publication
New York
Publisher
Humana Press
Date of Publication
c2014
Physical Description
1 online resource (xvi, 337 pages)
Series Title
Current clinical urology
ISBN
9781493911769 (electronic bk.)
9781493911752
Subjects (MeSH)
Drug Therapy, Combination
Molecular Targeted Therapy
Prostatic Neoplasms, Castration-Resistant - metabolism
Prostatic Neoplasms, Castration-Resistant - therapy
Receptors, Androgen - therapeutic use
Subjects (LCSH)
Prostate - Cancer - Treatment
Oncology
Interventional radiology
Abstract
This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in-depth review of proven therapeutic options, including bone-targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigation are also reviewed. The text provides up-to-date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence-based medicine.
Contents
Part I. Castrate-Resistant Prostate Cancer: Clinical and Biological Considerations -- 1. Introduction—Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities -- 2. Evolution of Clinical States and the Castration Resistant Clinical Paradigm -- 3. Molecular Mechanisms of Prostate Cancer Progression After Castration -- 4. New Imaging Modalities -- Part II. Treatment: The Androgen Receptor Signaling Axis Biology and Therapeutic Opportunities, Systemic Chemotherapy, Immunotherapy, Bone Targeted Approaches and Radiopharmaceuticals -- 5. Androgen Receptor Biology in Castration Resistant Prostate Cancer -- 6. The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer -- 7. Approaches Targeting Androgen Synthesis (CYP 17 Inhibitors) -- 8. Cytotoxic Chemotherapy (Taxanes and Taxane Combinations) -- 9. The Emerging Role of Immunotherapy in Castrate- Resistant Prostate Cancer -- 10. Bone-Targeted Therapy: Rationale and Current Status -- 11. Radium-223 and Other Radiopharmaceuticals in Prostate Cancer -- Part III. New Drug Development: Clinical Trials Design in CRPC -- 12. Introduction -- 13. Phase I–II Targeted Treatments -- 14. Defining Clinical Endpoints in Castration-Resistant Prostate Cancer -- Part IV. New Drug Development: Specific Targets -- 15. Angiogenesis Inhibition in Castration-Resistant Prostate Cancer -- 16. Co-targeting Adaptive Survival Pathways -- 17. Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer -- 18. PARP Inhibitors -- 19. Targeting C-Met/VEGF in Castration Resistant Prostate Cancer -- 20. Epigenetics in Castration Resistant Prostate Cancer -- 21. Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype -- Part V. Clinical Management Aspects -- 22. Strategies Addressing Quality of Life: Management of Patient-Reported Outcomes and Symptoms -- 23. Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development.
Format
e-Book
Location
Online
Less detail

Molecular and cellular therapies for motor neuron diseases

https://libcat.nshealth.ca/en/permalink/provcat42112
edited by Nicholas Boulis, Deirdre O’Connor and Anthony Donsante. --London, UK: Elsevier , c2017.
Available Online
View e-Book
Access
Registration required for PDF access.
Location
Online
Molecular and Cellular Therapies for Motor Neuron Diseases discusses the basics of the diseases, also covering advances in research and clinical trials. The book provides a resource for students that will help them learn the basics in a detailed manner that is required for scientists and clinicians.
Available Online
View e-Book
Other Authors
Boulis, Nicholas
Responsibility
edited by Nicholas Boulis, Deirdre O’Connor and Anthony Donsante
Alternate Title
Molecular & cellular therapies for motor neuron diseases
Place of Publication
London, UK
Publisher
Elsevier
Date of Publication
c2017
Physical Description
1 online resource, 336 p.
ISBN
9780128022573
Subjects (MeSH)
Cell- and Tissue-Based Therapy - methods
Molecular Targeted Therapy - methods
Motor Neuron Disease - therapy
Abstract
Molecular and Cellular Therapies for Motor Neuron Diseases discusses the basics of the diseases, also covering advances in research and clinical trials. The book provides a resource for students that will help them learn the basics in a detailed manner that is required for scientists and clinicians.
Access
Registration required for PDF access.
Format
e-Book
Location
Online
Less detail

Molecular and cellular therapies for motor neuron diseases

https://libcat.nshealth.ca/en/permalink/provcat50936
Boulis, Nicholas. --Philadelphia, PA: Elsevier , 2017.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Boulis, Nicholas
Place of Publication
Philadelphia, PA
Publisher
Elsevier
Date of Publication
2017
ISBN
9780128022573
Subjects (MeSH)
Motor Neuron Disease - therapy
Molecular Targeted Therapy - methods
Cell-and Tissue-Based Therapy - methods
Notes
Access to this online resource is restricted to IWK Health Centre employees working from inside the hospital network.
Format
e-Book
Location
Online
Less detail

The molecular basis of cancer

https://libcat.nshealth.ca/en/permalink/provcat32894
[edited by] John Mendelsohn, Joe W. Gray, Peter M. Howley ... [et al.]. (4th ed.) --Philadelphia, PA: Saunders Elsevier , c2015.
Available Online
View e-Book
Access
Registration required for PDF access.
Location
Online
The Molecular Basis of Cancer arms you with the latest knowledge and cutting-edge advances in the battle against cancer. This thoroughly revised, comprehensive oncology reference explores the scientific basis for our current understanding of malignant transformation and the pathogenesis and treatment of this disease. A team of leading experts thoroughly explains the molecular biologic principles that underlie the diagnostic tests and therapeutic interventions now being used in clinical trials …
Available Online
View e-Book
Other Authors
Mendelsohn, John
Responsibility
[edited by] John Mendelsohn, Joe W. Gray, Peter M. Howley ... [et al.]
Edition
4th ed.
Place of Publication
Philadelphia, PA
Publisher
Saunders Elsevier
Date of Publication
c2015
Physical Description
1 online resource (863 p.)
ISBN
9781455740666
Subjects (MeSH)
Neoplasms - genetics
Neoplasms - pathology
Molecular Biology - methods
Molecular Targeted Therapy
Abstract
The Molecular Basis of Cancer arms you with the latest knowledge and cutting-edge advances in the battle against cancer. This thoroughly revised, comprehensive oncology reference explores the scientific basis for our current understanding of malignant transformation and the pathogenesis and treatment of this disease. A team of leading experts thoroughly explains the molecular biologic principles that underlie the diagnostic tests and therapeutic interventions now being used in clinical trials and practice. Detailed descriptions of topics from molecular abnormalities in common cancers to new approaches for cancer therapy equip you to understand and apply the complexities of ongoing research in everyday clinical application. Effectively determine the course of malignancy and design appropriate treatment protocols by understanding the scientific underpinnings of cancer. Visually grasp and retain difficult concepts easily thanks to a user-friendly format with abundant full-color figures. Find critical information quickly with chapters following a logical sequence that moves from pathogenesis to therapy.
Access
Registration required for PDF access.
Format
e-Book
Location
Online
Less detail

Molecular basis of cancer, The

https://libcat.nshealth.ca/en/permalink/provcat50937
Mendelsohn, John. (4th ed.) --Philadelphia, PA: Elsevier , 2015.
Available Online
View e-Book
Location
Online
Available Online
View e-Book
Author
Mendelsohn, John
Edition
4th ed.
Place of Publication
Philadelphia, PA
Publisher
Elsevier
Date of Publication
2015
ISBN
9781455740666
Subjects (MeSH)
Neoplasms - genetics
Neoplasms - pathology
Molecular Biology - methods
Molecular Targeted Therapy
Notes
Access to this online resource is restricted to IWK Health Centre employees working from inside the hospital network.
Format
e-Book
Location
Online
Less detail

Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy

https://libcat.nshealth.ca/en/permalink/provcat43374
Yutaka Shimada, Katsuhiko Yanaga, editors. --Singapore: Springer , c2018.
Available Online
View e-Book
Location
Online
This volume focuses on the clinical applications of molecular diagnosis and targeted therapy from the viewpoint of oncologists specializing in specific organs. In addition, it discusses the role of molecular diagnosis and targeted therapy in the course of surgical treatment. Recent, rapid advances in molecular biology have shed new light on the mechanisms of cancer progression, and molecularly targeted drugs have been used to treat a variety of malignant diseases. For the diagnosis and precise …
Available Online
View e-Book
Other Authors
Shimada, Yutaka
Yanaga, Katsuhiko
Responsibility
Yutaka Shimada, Katsuhiko Yanaga, editors
Place of Publication
Singapore
Publisher
Springer
Date of Publication
c2018
Physical Description
1 online resource (viii, 156 p.) : 42 illus., 35 illus. in color
Series Title
Current human cell research and applications
ISBN
9789811064692
9789811064685 (print ed.)
9789811064708 (print ed.)
ISSN
2522-073X
Subjects (MeSH)
Gastrointestinal Neoplasms - diagnosis
Gastrointestinal Neoplasms - genetics
Molecular Diagnostic Techniques - methods
Molecular Targeted Therapy - methods
Thoracic Neoplasms - diagnosis
Thoracic Neoplasms - genetics
Specialty
Medical Oncology
Molecular Medicine
Abstract
This volume focuses on the clinical applications of molecular diagnosis and targeted therapy from the viewpoint of oncologists specializing in specific organs. In addition, it discusses the role of molecular diagnosis and targeted therapy in the course of surgical treatment. Recent, rapid advances in molecular biology have shed new light on the mechanisms of cancer progression, and molecularly targeted drugs have been used to treat a variety of malignant diseases. For the diagnosis and precise treatment of cancer, analysis of the molecular background of the tumor is indispensable. However, there are both tumor-specific and comprehensive mechanisms involved in these processes. Accordingly, a firm grasp of molecular diagnosis and targeted therapies for different tumors is vital for clinicians and basic researchers alike. This book provides essential information and the latest findings on molecular diagnosis and targeted therapy for thoracic and gastrointestinal malignancies. Though primarily intended for clinical and basic oncologists, it also offers a useful guide for clinicians who are interested in this field and are considering getting started in molecular diagnosis and targeted therapy.
Contents
1. Molecular biology of lung cancer in relation to precision medicine -- 2. Molecular diagnosis and targeting for breast cancer -- 3. Clinical application of stem cell biology in esophageal cancer -- 4. Molecular diagnosis and targeted therapy for gastric cancer -- 5. Molecular diagnosis and targeted therapy for colorectal cancer -- 6. Molecular and immunologic targets for the treatment of hepatocellular carcinoma -- 7. Molecular diagnosis and targeting for biliary tract cancer -- 8. Molecular analysis for therapeutic targets of pancreatic cancer -- 9. Molecular targeted therapy and diagnosis for gastroenteropancreatic neuroendocrine tumors.
Format
e-Book
Location
Online
Less detail

Molecular Pathology of Lung Cancer

https://libcat.nshealth.ca/en/permalink/provcat30969
Philip T. Cagle ... [et al.], editors. --New York, NY: Springer , c2012.
Available Online
View e-Book
Location
Online
As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, …
Available Online
View e-Book
Other Authors
Cagle, Philip T
Responsibility
Philip T. Cagle ... [et al.], editors
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2012
Physical Description
1 online resource (xi, 216 p. : 46 ill. in color)
Series Vol.
v. 6
Series Title
Molecular pathology library
ISBN
9781461431978
Subjects (MeSH)
Lung Neoplasms - pathology
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Pathology, Molecular - methods
Subjects (LCSH)
Oncology
Pathology
Thoracic surgery
Abstract
As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff.
Contents
Part I. Molecular Pathology of Lung Cancer: General Principles -- Approach to Personalized Care of the Lung Cancer Patient -- Etiology of Lung Cancer -- Genetic Susceptibility to Lung Cancer -- Lung Cancer Stem Cells -- The Classification of Pre-Invasive Lesions -- Molecular Pathology of Precursor and Pre-Invasive Lesions -- Revised Classification for Adenocarcinoma -- Molecular Basis for the Current Lung Cancer Classification -- Molecular Diagnosis of Lung Cancer -- Molecular Targeted Therapy of Lung Cancer -- Molecular Prognostic Markers of Lung Cancer -- New Techniques for Optical and Molecular Visualization of Lung Cancer -- Part II. Molecular Pathology of Lung Cancer: Specific Histologic Types -- Adenocarcinoma -- Squamous Cell Carcinoma -- Molecular Pathology of Large Cell Carcinoma -- Molecular Pathology of Small Cell Carcinomas -- Molecular Biopsy of Neuroendocrine Carcinomas Other Than Small Cell Carcinoma -- Molecular Pathology of Uncommon Carcinomas -- Biology of Lung Cancer Metastases.
Format
e-Book
Location
Online
Less detail

Molecular Pathology of Nervous System Tumors : Biological Stratification and Targeted Therapies

https://libcat.nshealth.ca/en/permalink/provcat38980
Matthias A. Karajannis, David Zagzag, editors. --New York, NY: Springer , c2015.
Available Online
View e-Book
Location
Online
This book serves as a comprehensive guide to the rapidly evolving field of molecular neuropathology of nervous system tumors, as well as the underlying biology and emerging molecular targeted therapies. Special emphasis is given to already established and emerging molecular diagnostic tests in neuropathology, as well as molecular targeted therapies. The book is organized by clinico-pathologic disease entities, and each chapter is written by a team of experts in their field. Molecular Pathology …
Available Online
View e-Book
Other Authors
Karajannis, Matthias A
Zagzag, David
Responsibility
Matthias A. Karajannis, David Zagzag, editors
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2015
Physical Description
1 online resource (xv, 247 p. : 121 illus., 78 illus. in color)
Series Title
Molecular pathology library
ISBN
9781493918300
9781493918294 (print ed.)
ISSN
1935-987X
Subjects (MeSH)
Biomarkers, Tumor
Central Nervous System Neoplasms - genetics
Central Nervous System Neoplasms - pathology
Central Nervous System Neoplasms - therapy
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Abstract
This book serves as a comprehensive guide to the rapidly evolving field of molecular neuropathology of nervous system tumors, as well as the underlying biology and emerging molecular targeted therapies. Special emphasis is given to already established and emerging molecular diagnostic tests in neuropathology, as well as molecular targeted therapies. The book is organized by clinico-pathologic disease entities, and each chapter is written by a team of experts in their field. Molecular Pathology of Nervous System Tumors is of great value and utility for physicians and scientists involved with or interested in the up-to-date diagnosis and treatment of patients with brain tumors.
Contents
[publisher supplied] 1. Hereditary Predisposition to Primary CNS Tumors -- 2. Brain Tumor Stem Cells -- 3. Molecular Pathology Techniques -- 4. Low-grade Gliomas -- 5. Ependymoma -- 6. Adult High-Grade (Diffuse) Glioma -- 7. High-Grade Gliomas and DIPG (Pediatric) -- 8.Oligodendroglial Tumors: Current Treatments and the Promise of Molecular Genetics -- 9.Molecular Pathology of Nervous System Tumors: Medulloblastoma and CNS Primitive Neuroectodermal Tumors -- 10. Subependymal Giant Cell Astrocytoma -- 11. Germ Cell Tumors -- 12. Choroid Plexus Tumors. -- 13. Atypical Teratoid Rhabdoid Tumors -- 14. Hemangioblastoma -- 15. Schwannomas -- 16. Molecular Pathology of Nervous System Tumors -- 17. Molecular Genetic Pathology of Meningiomas.
Format
e-Book
Location
Online
Less detail

Molecular Radio-Oncology

https://libcat.nshealth.ca/en/permalink/provcat40379
Michael Baumann, Mechthild Krause, Nils Cordes, editors. --Berlin, Heidelberg: Springer , c2016.
Available Online
View e-Book
Location
Online
This book concisely reviews our current understanding of hypoxia, molecular targeting, DNA repair, cancer stem cells, and tumor pathophysiology, while also discussing novel strategies for putting these findings into practice in daily clinical routine. Radiotherapy is an important part of modern multimodal cancer treatment, and the past several years have witnessed not only substantial improvements in radiation techniques and the use of new beam qualities, but also major strides in our understan…
Available Online
View e-Book
Other Authors
Baumann, Michael
Krause, Mechthild
Cordes, Nils
Responsibility
Michael Baumann, Mechthild Krause, Nils Cordes, editors
Place of Publication
Berlin, Heidelberg
Publisher
Springer
Date of Publication
c2016
Physical Description
1 online resource (ix, 201 p. : 30 illus., 24 illus. in color)
Series Vol.
v. 198
Series Title
Recent results in cancer research
ISBN
9783662496510
9783662496497 (print ed.)
ISSN
0080-0015
Subjects (MeSH)
Molecular Targeted Therapy
Radiotherapy - methods
Abstract
This book concisely reviews our current understanding of hypoxia, molecular targeting, DNA repair, cancer stem cells, and tumor pathophysiology, while also discussing novel strategies for putting these findings into practice in daily clinical routine. Radiotherapy is an important part of modern multimodal cancer treatment, and the past several years have witnessed not only substantial improvements in radiation techniques and the use of new beam qualities, but also major strides in our understanding of molecular tumor biology and tumor radiation response. Against this backdrop, the book highlights recent efforts to identify reasonable and clinically applicable biomarkers using broad-spectrum tissue microarrays and high-throughput systems biology approaches like genomics and epigenomics. In particular, it describes in detail how such molecular information is now being exploited for diagnostic imaging and imaging throughout treatment using the example of positron emission tomography. By discussing all these issues in the context of modern radiation oncology, the book provides a broad, up-to-date overview of the molecular aspects of radiation oncology that will hopefully foster its further optimization.
Contents
DNA Repair -- Cancer Stem Cells -- Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology -- Molecular Targeting of Integrins and Integrin-Associated Signaling Networks in Radiation Oncology -- Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors -- Hypoxia as a Biomarker and for Personalized Radiation Oncology -- Human Papilloma Virus as a Biomarker for Personalized Head and Neck Cancer Radiotherapy -- FDG and Beyond -- On the Reliability of Automatic Volume Delineation in Low-Contrast [18F]FMISO-PET Imaging -- FMISO as a Biomarker for Clinical Radiation Oncology.
Format
e-Book
Location
Online
Less detail

Molecular Targeted Therapy of Lung Cancer

https://libcat.nshealth.ca/en/permalink/provcat41952
Yuichi Takiguchi, editor. --Singapore: Springer , 2017.
Available Online
View e-Book
Location
Online
This book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wide variety of resistance mechanisms using new-generation molecular targeted agents and potential novel approaches. It also outlines the increasing necessity for new diagnostic technology and strategies for managing different adverse effects and …
Available Online
View e-Book
Other Authors
Takiguchi, Yuichi
Responsibility
Yuichi Takiguchi, editor
Place of Publication
Singapore
Publisher
Springer
Date of Publication
2017
Physical Description
1 online resource (x, 327 pages) : 54 illus., 48 illus. in color
ISBN
9789811020025
9789811020001 (print ed.)
Subjects (MeSH)
Lung Neoplasms - drug therapy
Molecular Targeted Therapy - methods
Abstract
This book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wide variety of resistance mechanisms using new-generation molecular targeted agents and potential novel approaches. It also outlines the increasing necessity for new diagnostic technology and strategies for managing different adverse effects and novel methods for evaluating effectiveness and safety. Edited and authored by opinion leaders, Molecular Targeted Therapy of Lung Cancer provides a comprehensive overview of the disease and its treatments. It is a valuable resource for graduate students, post-doctoral fellows and faculty staff, as well as researchers involved in clinical and translational research on lung cancer, helping promote new ideas for further advances.
Contents
Part I: Diagnosis -- 1. Classification of adenocarcinoma of the lung - with a special reference to prognosis -- 2. Screening lung cancer with low dose CT combined with molecular markers -- 3. PET-CT, bio-imaging for predicting prognosis and response to chemotherapy in patients with lung cancer -- 4. Methods in molecular diagnosis -- 5. Accurate nodal staging and biomarker testing with endobronchial ultrasound-guided transbronchial needle aspiration -- 6. Next generation sequencing and bioinformatics -- 7. Companion diagnostics -- Part II: Treatment -- 8. Small cell lung cancer and molecular targeted therapy -- 9. Locally advanced non-small cell lung cancer and molecular targeted therapy -- 10. EGFR mutant -- 11. ALK mutant -- 12. Minor-driver mutant -- 13. Mechanism of resistance to targeted molecular therapy -- 14. Immunotherapy -- 15. Lung cancer complicated with interstitial lung diseases -- 16. Management of adverse effects by molecular targeted therapy and immunotherapy -- Part III: Evaluation -- 17. Health related-quality of life in molecular targeted therapy -- 18. Gene signature -- Part IV: Novel approach -- 19. Targeting epithelial-mesenchymal transition and cancer stem cell -- 20. Targeting the lung cancer microenvironment: harnessing host responses.
Format
e-Book
Location
Online
Less detail

Molecular Targeting in Oncology

https://libcat.nshealth.ca/en/permalink/provcat40635
edited by Howard L. Kaufman, Scott Wadler, Karen Antman. --Totowa, NJ: Humana Press , c2008.
Available Online
View e-Book
Location
Online
In Molecular Targeting in Oncology, authors present an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice. The volume is divided into five sectio…
Available Online
View e-Book
Other Authors
Kaufman, Howard L
Wadler, Scott
Antman, Karen
Responsibility
edited by Howard L. Kaufman, Scott Wadler, Karen Antman
Place of Publication
Totowa, NJ
Publisher
Humana Press
Date of Publication
c2008
Physical Description
1 online resource (XVI, 728 p
Series Title
Cancer drug discovery and development
ISBN
9781597453370
9781588295774 (print ed.)
Subjects (MeSH)
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Drug Design
Drug Evaluation
Molecular Targeted Therapy
Neoplasms - drug therapy
Abstract
In Molecular Targeting in Oncology, authors present an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice. The volume is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second section describes how clinicians are evaluating targeted therapies in specific organ systems. The third section illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth section details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more. Comprehensive and cutting-edge, Molecular Targeting in Oncology is an essential reference for those working in the field.
Contents
Part I. General Strategies for Molecular Targeting in Oncology -- The Cell Cycle: Therapeutic Targeting of Cell Cycle Regulatory Components and Effector Pathways in Cancer -- mTOR: Properties and Therapeutics -- Ras/Raf/MEK Inhibitors -- 17-AAG: Targeting the Molecular Chaperone Heat Shock Protein 90 -- The Cancer Epigenome: Can it be Targeted for Therapy? -- Part II. Molecular Targeting for Specific Disease Sites -- Molecular Targeting in Upper Gastrointestinal Malignancies -- Molecular Targeting of Colorectal Cancer: An Idea Whose Time Has Come? -- Molecular Targeting in Hepatocellular Carcinoma -- Molecularly Targeted Therapy in Pancreatic Cancer -- Untargeted Use of Targeted Therapy: A Dilemma in Non-Small Cell Lung Cancer -- Renal Cell Carcinoma: Renal Cell Cancer -- Targeted Therapies for Prostate Cancer -- Molecular Targets in Ovarian Cancer and Endometrial Cancer -- Targeted Therapy For Breast Cancer -- Melanoma -- Part III. Classes of Drugs for Molecular Targeting in Oncology -- Antibody Therapy of Cancer -- Nucleic Acid Therapies for Cancer Treatment -- Engineering Oncolytic Measles Viruses for Targeted Cancer Therapy -- Vaccines as Targeted Cancer Therapy -- Cytokine-Based Therapy for Cancer -- Cyclooxygenase-2 as a Target for Cancer Prevention and Treatment -- Part IV. Specific Drugs for Molecular Targeting in Oncology -- Imatinib Mesylate (Gleevec®) and the Emergence of Chemotherapeuticss Drug-Resistant Mutations -- Development of a Targeted Treatment for Cancer: The Example of C225 (Cetuximab) -- VEGF Inhibition for Cancer Therapy -- Somatostatin Analogue Therapy -- Part V. Challenges in Molecular Targeting in Oncology -- Patient Selection for Rational Development of Novel Anticancer Agents -- Clinical Trial Design with Targeted Agents -- How to Define Treatment Success or Failure if Tumors Do Not Shrink: Consequences for Trial Design -- Molecular Imaging in Oncology -- Combinations of Molecular-Targeted Therapies: Opportunities and Challenges -- Preclinical Development of Molecularly Targeted Agents in Oncology.
Format
e-Book
Location
Online
Less detail

Nuclear Medicine in Oncology : Molecular Imaging and Target Therapy

https://libcat.nshealth.ca/en/permalink/provcat44463
Gang Huang, editor. --Singapore: Springer ; Shanghai Jiao Tong University Press , c2019.
Available Online
View e-Book
Location
Online
This book introduces molecular imaging and target therapy in various cancers. The first part is the subjects and primary focused on the basics of nuclear physics, radiation dosimetry, nuclear medicine equipment and small animal imaging equipment. The second part is about the radiopharmaceutical and commonly used clinical radiopharmaceuticals, including positron emission imaging agent, single photon emission imaging agent, and radionuclide therapy agents as well as their radioactive preparation,…
Available Online
View e-Book
Other Authors
Huang, Gang
Responsibility
Gang Huang, editor
Place of Publication
Singapore
Publisher
Springer ; Shanghai Jiao Tong University Press
Date of Publication
c2019
Physical Description
1 online resource (xi, 346 p.) : 247 illus., 157 illus. in color
ISBN
9789811374586
9789811374579 (Print ed.)
9789811374593 (Print ed.)
9789811374609 (Print ed.)
Subjects (MeSH)
Molecular Imaging
Molecular Targeted Therapy
Neoplasms - diagnostic imaging
Neoplasms - radiotherapy
Specialty
Diagnostic Imaging
Medical Oncology
Abstract
This book introduces molecular imaging and target therapy in various cancers. The first part is the subjects and primary focused on the basics of nuclear physics, radiation dosimetry, nuclear medicine equipment and small animal imaging equipment. The second part is about the radiopharmaceutical and commonly used clinical radiopharmaceuticals, including positron emission imaging agent, single photon emission imaging agent, and radionuclide therapy agents as well as their radioactive preparation, quality control, and a brief clinical application were included. Also, this part introduces a number of new imaging agents which were potential value of clinical applications. In the third part, the clinical application of the conventional imaging agent 18F-FDG in different tumors and neurodegenerative diseases and 18F-Dopa imaging in the nervous system are discussed. Besides the clinical applications of 99mTc labeled radiopharmaceuticals in parathyroid disease, coronary heart disease, myocardial infarction, sentinel lymph node, metastatic bone tumors, liver and gallbladder disease in children are introduced. Finally, the applications of radionuclide 131I on treatments of Graves' disease and differentiated thyroid cancer and metastases are investigated respectively. This book is a useful reference for professionals engaged in nuclear medicine and clinical research, including clinical nuclear medicine physicians, nuclear medicine engineers and nuclear medicine pharmacists.
Contents
1. Glucose metabolism imaging -- 2. Clinical utility of 18F-FDG PET/CT in breast cancer management and targeted therapy -- 3. The application of 18F-FDG PET/CT in diagnose and therapy of non-small cell lung cancer -- 4. Clinical application of 18F-FDG PET/CT in lymphoma -- 5. Clinical utility of 18F-FDG PET/CT scanning in urological cancers management -- 6. Gynecologic tumor PET / CT imaging -- 7. Molecular imaging and targeted therapy of gastrointestinal cancer -- 8. Head and neck cancer -- 9. Molecular imaging and targeted therapy of malignant melanoma -- 10. Role of 18F-FDG PET/CT in pediatric oncology -- 11. Molecular imaging -- 12. Receptor targeted radionuclide imaging (RTRI) and peptide receptor radionuclide therapy (PRRT) -- 13. Radioimmunoimaging and targeted therapy -- 14. Apoptosis imaging -- 15. Radionuclide gene and reporter gene imaging -- 16. Na+/I- symporter target for thyroid disease imaging and treatment -- 17. Molecular imaging and targeted therapy in neurology -- 18. Nuclear cardiolgy -- 19. Equipment for imaging and mechanism, radiation protection -- 20. Molecular imaging probe.
Format
e-Book
Location
Online
Less detail

Personalized Management of Gastric Cancer : Translational and Precision Medicine

https://libcat.nshealth.ca/en/permalink/provcat41986
Jia Wei, Baorui Liu, editors. --Singapore: Springer , 2017.
Available Online
View e-Book
Location
Online
This book offers essential information on basic and translational research in gastric cancer, while also illustrating potential opportunities for its application in clinical practice. Gastric cancer is the fourth-most-common cancer globally and the second-leading cause of cancer deaths. It is known to be a heterogeneous disease with varied responses to one-size-fits-all treatments. Expanding our knowledge of cancer cell genetics may help us to explore more effective treatments in gastric cancer…
Available Online
View e-Book
Other Authors
Wei, Jia
Liu, Baorui
Responsibility
Jia Wei, Baorui Liu, editors
Place of Publication
Singapore
Publisher
Springer
Date of Publication
2017
Physical Description
1 online resource (viii, 227 pages) : 34 illus., 32 illus. in color
ISBN
9789811039782
9789811039775 (print ed.)
Subjects (MeSH)
Immunotherapy - methods
Molecular Targeted Therapy - methods
Nanomedicine - methods
Precision Medicine - methods
Stomach Neoplasms - therapy
Abstract
This book offers essential information on basic and translational research in gastric cancer, while also illustrating potential opportunities for its application in clinical practice. Gastric cancer is the fourth-most-common cancer globally and the second-leading cause of cancer deaths. It is known to be a heterogeneous disease with varied responses to one-size-fits-all treatments. Expanding our knowledge of cancer cell genetics may help us to explore more effective treatments in gastric cancer. The research on molecular mechanisms and its clinical applications, both presented here, will help readers gain an in-depth understanding of gastric cancer and its effective treatment. The book's four sections cover personalized medicine, precise regional therapy, immunotherapy and nanomedicine in gastric cancer. Each part presents the state of art, recent advances and the authors' experiences. Moreover, several interesting cases are described to demonstrate how gastric cancer patients benefit from translational research. This informative and attractively presented book on precision treatment in gastric cancer, including experimental findings and clinical treatment options, offers a valuable resource for oncologists and graduate students working in the field of gastric cancer. Jia Wei, MD, PhD, is an associate professor at Nanjing University and the vice director of Clinical Cancer Institute of Nanjing University. She is now working as an oncologist in the Comprehensive Cancer Center, Affiliated Drum Tower Hospital to Medical School of Nanjing University. Baorui Liu, MD, PhD, is a professor at Nanjing University and director of the Clinical Cancer Institute of Nanjing University. He is also the director of the Comprehensive Cancer Center of Drum Tower Hospital.
Contents
Part I: Personalized Therapy in Gastric Cancer -- Molecular pathology of hereditary gastric cancer -- Genetics and molecular signature of gastric cancer -- Circulating tumor cells in gastric cancer -- Customized chemotherapy in advanced gastric cancer -- Targeted therapy in advanced gastric cancer -- Part II: Precision Regional Therapy in Gastric Cancer -- Laparoscopic surgery and robotic surgery -- Radiotherapy in peritoneal metastatic gastric cancer -- Personalized intraperitoneal strategy in gastric cancer -- Part III: Immunotherapy -- Immune checkpoint blockade therapy of gastric cancer -- Adoptive cell therapy of gastric cancer -- Combinational immunotherapy of gastric cancer -- Part IV: Use of Nanomedicine in the Diagnosis and Treatment of Gastric Cancer -- Use of Nanomedicine in the diagnosis of gastric cancer -- Systemic drug delivery -- Local drug delivery -- Drug delivery in synergistic combination with other treatments.
Format
e-Book
Location
Online
Less detail

Precision Molecular Pathology of Breast Cancer

https://libcat.nshealth.ca/en/permalink/provcat39035
Ashraf Khan, Ian O. Ellis, Andrew M. Hanby, Ediz F. Cosar, Emad A. Rakha, Dina Kandil, editors. (1st ed.) --New York, NY: Springer , c2015.
Available Online
View e-Book
Location
Online
This volume provides a comprehensive review of the molecular mechanisms involved in precancerous lesions and benign and malignant breast tumors. Given the complex molecular pathways in breast cancer biology, the book simplifies these complex mechanisms and highlights the practical issues important for daily practice. Sections are structured to review breast carcinogenesis and the role of familial predisposition and stem cells in initiation and progression of breast cancer. In-depth chapters pre…
Available Online
View e-Book
Other Authors
Khan, Ashraf
Ellis, Ian O
Hanby, Andrew M
Cosar, Ediz F
Rakha, Emad A
Kandil, Dina
Responsibility
Ashraf Khan, Ian O. Ellis, Andrew M. Hanby, Ediz F. Cosar, Emad A. Rakha, Dina Kandil, editors
Edition
1st ed.
Place of Publication
New York, NY
Publisher
Springer
Date of Publication
c2015
Physical Description
1 online resource (x, 338 p. : 29 illus., 28 illus. in color)
Series Vol.
10
Series Title
Molecular pathology library
ISBN
9781493928866
9781493928859 (print ed.)
ISSN
1935-987X
Subjects (MeSH)
Breast neoplasms - pathology
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Pathology, Molecular - methods
Abstract
This volume provides a comprehensive review of the molecular mechanisms involved in precancerous lesions and benign and malignant breast tumors. Given the complex molecular pathways in breast cancer biology, the book simplifies these complex mechanisms and highlights the practical issues important for daily practice. Sections are structured to review breast carcinogenesis and the role of familial predisposition and stem cells in initiation and progression of breast cancer. In-depth chapters present morphologic and molecular correlations in precancerous and malignant breast lesions, while outlining highly practical issues that are in practice today in breast pathology, such as evaluation of estrogen, progesterone receptors, and HER-2. Written by experts in the field, Precision Molecular Pathology of Breast Cancer is a valuable resource that covers the current practice of breast pathology and looks into the future with an emphasis on the molecular basis of breast cancer.
Contents
Molecular basis of breast cancer imaging -- Familial Breast Cancer and Genetic Predisposition in Breast Cancer -- Modelling the Molecular Pathology of Breast Cancer Initiation -- Molecular Pathology of Precancerous Lesions of the Breast -- Breast Cancer Stem Cells: Role in Tumor Initiation, Progression and Targeted Therapy -- Molecular Pathology of Pre-Invasive Ductal Carcinoma -- Molecular Pathology of Lobular Carcinoma -- Molecular Pathology of Hormone Regulation in Breast Cancer: Hormone Receptor Evaluation and Therapeutic Implications -- Molecular Pathology of HER Family of Oncogenes in Breast Cancer: HER-2 Evaluation and Role in Targeted Therapy -- Molecular Classification of Breast Cancer -- Triple-Negative Breast Cancer: Subtypes with Clinical Implications -- Molecular-based Diagnostic, Prognostic and Predictive Tests in Breast Cancer -- Role of MicroRNAs in Breast Cancer -- Molecular Pathology of Fibroepithelial Neoplasms of the Breast -- Molecular Features of Mesenchymal Tumors of the Breast -- Molecular Pathology of Breast Cancer Metastasis -- The molecular pathology of chemoresistance during the therapeutic response in breast cancer -- The Molecular Pathology of Male Breast Cancer -- Specimens for Molecular Testing in Breast Cancer.
Format
e-Book
Location
Online
Less detail

35 records – page 1 of 2.